Publications

Bunch AG, Perry CS, Abraham L, Wikoff DS, Tachovsky JA, Hixon JG, Urban JD, Harris MA, Haws LC. 2014. Evaluation of impact of shale gas operations in the Barnett Shale region on volatile organic compounds in air and potential human health risks. Sci Tot Environ 468-469(Jan 15):832-842; doi: 10.1016/j.scitotenv.2013.08.080. PMID: 24076504.

Urban JD, Wikoff DS, Bunch ATG, Harris MA, Haws LC. 2014. A review of background dioxin concentrations in urban/suburban and rural soils across the United States: Implications for site assessments and the establishment of soil cleanup levels. Sci Tot Environ 466-467:(Jan 1)586-597; doi: 10.1016/j.scitotenv.2013.07.065.

Thompson CM, Kirman CR, Proctor DM, Haws LC, Suh M, Hays S, Hixon JG, Harris MA. 2014. A chronic oral reference dose for hexavalent chromium-induced intestinal cancer. J Appl Toxicol 34:525-536. doi: 10.1002/jat.2907.

Suh M, Thompson C, Kirman C, Carakostas M, Haws LC, Harris M, Proctor D. 2014. High concentrations of hexavalent chromium in drinking water alter iron homeostasis in F344 rats and B6C3F1 mice. Food Chem Toxicol 65:381-388; doi: 10.1016/j.fct.2014.01.009.

Kirman CR, Aylward LL, Suh M, Harris MA, Thompson CM, Haws LC, Proctor DM, Lin SS, Parker W, Hays SM. 2013. Physiologically based pharmacokinetic model for humans orally exposed to chromium. Chem Biol Interact 204(1):13-27. doi:pii: S0009-2797(13)00082-3. 10.1016/j.cbi.2013.04.003.

Dourson ML, Gadagbui B, Griffin S, Garabrant DH, Haws LC, Kirman C, Tohyama C. 2013. The importance of problem formulations in risk assessment: A case study involving dioxin-contaminated soil. Regul Toxicol Pharmacol 66(2):208-216; doi: 10.1016/j.yrtph.2013.03.010.

Wikoff D, Fitzgerald L, Haws L, Harris M. Health-based framework for evaluating the safety of hydraulic fracturing products. Presented at Society of Toxicology 52nd Annual Meeting, San Antonio, TX, March 2013.

O’Brien T, Ding H, Suh M, Thompson C, Parsons BL, Harris MA, Winkelman WA, Wolf JC, Hixon JG, Schwartz AM, Myers MB, Haws LC, Proctor DM. 2013. Assessment of K-Ras mutant frequency and micronucleus incidence in the mouse duodenum following 90-days of exposure to Cr(VI) in drinking water. Mutat Res 754:15-21. doi: 10.1016/j.mrgentox.2013.03.008.

Suh M, Thompson CM, Hixon JG, Harris MA, Kirman CR, Hays S, Haws LC, Proctor DM. 2013. Potential involvement of oxidative stress and iron disturbance in the development of oral cavity tumors in rats exposed to hexavalent chromium. Presented at the Society of Toxicology’s 52nd Annual Meeting, March 10-14, San Antonio, TX.

Thompson CM, Proctor DM, Suh M, Haws LC, Kirman CR, Harris MA. 2013. Assessment of the mode of action underlying development of rodent small intestinal tumors following oral exposure to hexavalent chromium and relevance to humans. Crit Rev Toxicol 43(3):244-274; doi: 10.3109/10408444.2013.768596.

Haws L, Hixon G, DeVito M, Walker N, Kuriakose L, Harris M, Birnbaum L, Wikoff D. Development of weighted distributions of relative potency estimates for dioxin-like compounds. Presented at Society of Toxicology 52nd Annual Meeting, San Antonio, TX, March 2013.

Urban JD, Thompson CM, Deskin R, Waite M, Haws LC. 2013. Development of an oral cancer slope factor for acrylamide based on tumors relevant to humans. Presented at Society of Toxicology 52nd Annual Meeting, San Antonio, TX, March 2013.

Thompson CM, Kirman CR, Proctor DM, Suh M, Hays SM, Haws LC, Harris MA. A chronic oral reference dose for hexavalent chromium. Presented at Society of Toxicology 52nd Annual Meeting, San Antonio, TX, March 2013.

Thompson CM, Gaylor DW, Tachovsky JA, Perry C, Carakostas MC, Haws LC. 2013. Development of a chronic noncancer oral reference dose and drinking water screening level for sulfolane using benchmark dose modeling. J Appl Toxicol 33(12):1395-1406; doi: 10.1002/jat.2799.

Kirman CR, Thompson CM, Proctor DM, Suh M, Haws LC, Harris MA, Hays SM. 2013. Using PBPK modeling to address diurnal variation and age differences in hexavalent chromium toxicokinetics in humans. Presented at Society of Toxicology 52nd Annual Meeting, March 10-14, San Antonio, TX.

Kirman, CR, Hays, SM, Aylward, LL, Suh, M, Harris, MA, Thompson, CM, Haws, LC, Proctor, DM. 2012. Physiologically based pharmacokinetic model for rats and mice orally exposed to chromium. Chem Biol Interact 200(1):45-64.

Kopec AK, Kim S, Forgacs AL, Zacharewski TR, Proctor DM, Harris MA, Haws LC, Thompson CM. 2012. Genome-wide gene expression effects in B6C3F1 mouse intestinal epithelia following 7 and 90 days of exposure to hexavalent chromium in drinking water. Toxicol Appl Pharmacol 259(1):13-26; doi: 10.1016/j.taap.2011.11.012.

Harris MA, Thompson CM, Wolf JC, Fedorov Y, Hixon JG, Proctor DM, Suh M, Haws LC. Assessment of genotoxic potential of Cr(VI) in the intestine via in vivo intestinal micronucleus assay and in vitro high content analysis in differentiated and undifferentiated caco-2. Presented at Society of Toxicology’s 51st Annual Meeting, San Francisco, CA, March 2012.

Proctor DM, Suh M, Aylward LL, Kirman CR, Harris MA, Thompson CM, Gürleyük H, Gerads R, Haws LC, Hays SM. 2012. Hexavalent chromium reduction kinetics in rodent stomach contents. Chemosphere 89(5):487-493; doi: 10.1016/j.chemosphere.2012.04.065.

Haws L, Fitzgerald L, Burkhalter K, Wikoff D. US EPA’s proposed toxicity values for TCDD: Implications for decision-making regarding the safety of foods in the United States. Presented at the Society of Toxicology’s 51st Annual Meeting, San Francisco, CA, March 2012.